Aspira Women's Health Inc. Stock: price and insider trades · United States · SEC (Form 4)

About Aspira Women's Health Inc.

Aspira Women’s Health Inc. is a U.S.-based specialty diagnostics company focused on women’s health, with its public-market history tied to the U.S. small-cap equity universe and, most recently, the Nasdaq Capital Market before its delisting from Nasdaq in April 2025. The company was originally incorporated in 1993 and completed its IPO in 2000. Its executive offices and principal operations are in Austin, Texas, with an additional administrative office in Shelton, Connecticut. ([sec.gov](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/awhl-20251231x10k.htm)) Aspira’s core business is the discovery, development, and commercialization of noninvasive, AI-powered tests intended to aid in the diagnosis of gynecologic diseases, beginning with ovarian cancer. Its commercial portfolio is marketed under the OvaSuite umbrella and includes Ova1Plus and OvaWatch; Overa is currently used as a reflex test within the Ova1Plus workflow. The company also operates Aspira Labs, a CLIA-certified clinical laboratory in Austin that specializes in biomarker-based risk assessment for gynecologic cancers and related disease states. ([sec.gov](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/awhl-20251231x10k.htm)) From a competitive standpoint, Aspira operates in a highly challenging women’s health diagnostics market where clinicians still have multiple conventional decision-making options and may not always order a specialized assay. Management identifies both traditional clinical pathways and specific competitors such as Fujirebio Diagnostics’ FDA-cleared ROMA test as meaningful competitive pressures on the Ova1Plus workflow. As a result, Aspira’s commercial strategy relies on demonstrating clinical utility, building physician adoption, and expanding reimbursement and distribution pathways. ([sec.gov](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/awhl-20251231x10k.htm)) Geographically, the company’s commercial footprint is primarily U.S.-national rather than international. It sells through a direct national sales force, including field sales and inside sales, markets tests directly to physicians through referral channels, and reaches laboratories via the Aspira Synergy platform. It also works with channel partners such as BioReference Health and ARUP, and in late 2024 expanded its BioReference collaboration to include OvaWatch, which suggests a continued push to deepen U.S. penetration through partner-led distribution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/926617/000092661726000020/awhl-20251231x10k.htm)) Recent developments underscore a company in transition. Aspira was notified in April 2025 that Nasdaq would delist its shares for failure to maintain the minimum stockholders’ equity requirement, after which the 2024 at-the-market program was terminated. In September 2025, the company completed a private placement with existing and new accredited investors, including board members. In its 2025 annual report, Aspira also said it remediated a previously identified material weakness in internal control over financial reporting by year-end 2025, and it highlighted its selection by ARPA-H for the Sprint for Women’s Health program in October 2024. ([sec.gov](https://www.sec.gov/Archives/edgar/data/926617/000092661725000008/awhl-20250930x10q.htm?utm_source=openai))